Prescription medicine
Dulaglutide Brand names: Trulicity
Dulaglutide (Trulicity) is a prescription medicine with an FDA approval on record since 2014. No generic is listed; pharmacies paid $487.57 per mL (Trulicity 0.75 mg/0.5 mL pen) in the October 7, 2026 NADAC survey.
- No generic listed
- Boxed warning
Check it at the source: the dulaglutide FDA label on DailyMed (effective June 16, 2026, Eli Lilly and Company); the BLA 125469 record on Drugs@FDA; every dulaglutide label on DailyMed.
Highlights of the record
FDA label of June 16, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
RISK OF THYROID C-CELL TUMORS.
In male and female rats, dulaglutide causes a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure. It is unknown whether TRULICITY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of dulaglutide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions ( 5.1 ), and Nonclinical Toxicology ( 13.1 )]. TRULICITY is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC with use of TRULICITY and inform them of symptoms of thyroid tumors (e.g., mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with TRULICITY [see Contraindications ( 4 ) and Warnings and Precautions ( 5.1 )]. WARNING: RISK OF THYROID C-CELL TUMORS See full prescribing information for complete boxed warning. Dulaglutide causes thyroid C-cell tumors in rats. […]
Used for
From the label: indications and usageTRULICITY ® is indicated: As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.
Forms and strengths
- 0.75 mg/.5ml
- 1.5 mg/.5ml
- 3 mg/.5ml
- 4.5 mg/.5ml
Injection (solution).
On the market
- Earliest approval on file
- September 18, 2014 Trulicity, Eli Lilly And Co; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 2 of which 0 under generic applications, 2 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $487.57 per mL Trulicity 0.75 mg/0.5 mL pen
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- 2 since 2021 0 Class I among all firms' recalls; latest April 5, 2022
- FAERS reports
- 88,160 through July 30, 2026
What is dulaglutide used for?
From the label: indications and usageTRULICITY ® is indicated: As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. To reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors. TRULICITY ® is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated ( 1 ): As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. […]
Conditions named in the indications of dulaglutide's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: GLP-1 Receptor Agonist.
Source: FDA drug label (Trulicity), Eli Lilly and Company, effective June 16, 2026 (SPL set 463050bd-2b1c-40f5-b3c3-0a04bb433309), via openFDA; the full label on DailyMed
What does the patient leaflet for dulaglutide say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What is the most important information I should know about TRULICITY?TRULICITY may cause serious side effects, including: Possible thyroid tumors, including cancer. Tell your healthcare provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer. In studies with rats or mice, TRULICITY and medicines that work like TRULICITY caused thyroid tumors, including thyroid cancer. It is not known if TRULICITY will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people. Do not use TRULICITY if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC), or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Source: FDA drug label (Trulicity), Eli Lilly and Company, effective June 16, 2026 (SPL set 463050bd-2b1c-40f5-b3c3-0a04bb433309), via openFDA; the full label on DailyMed
Is there a generic for dulaglutide (Trulicity)?
No generic dulaglutide is approved (Drugs@FDA, October 8, 2026).
- 2014 earliest approval on file
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for dulaglutide (Trulicity)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $487.57 per mL (Trulicity 0.75 mg/0.5 mL pen), up 2% from $478.10 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Trulicity 4.5 mg/0.5 mL pen (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Trulicity 0.75 mg/0.5 mL pen | Brand | $487.57 per mL | $243.79 per single-dose pen | +2% |
| Trulicity 1.5 mg/0.5 mL pen | Brand | $487.54 per mL | $243.77 per single-dose pen | +2% |
| Trulicity 3 mg/0.5 mL pen | Brand | $487.50 per mL | $243.75 per single-dose pen | +2% |
| Trulicity 4.5 mg/0.5 mL pen | Brand | $487.42 per mL | $243.71 per single-dose pen | +2% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Has dulaglutide been recalled?
The FDA's Enforcement Report lists 2 recalls naming dulaglutide since 2021: 0 Class I (the most serious), 2 Class II, 0 Class III; 0 still ongoing. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| April 5, 2022 | Class II | Cardinal Health Inc. | TEMPERATURE ABUSE: Products were exposed to temperatures outside of the products labeled storage conditions |
| August 19, 2021 | Class II | Eli Lilly & Company | Labeling: Label error on declared strength - autoinjector devices labeled as 0.75 mg / 0.5 mL actually contain 1.5 mg / 0.5 mL of product. |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the dulaglutide label say about other medicines?
The dulaglutide label names 2 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Liraglutide | warnings and precautions | Cases of MTC in patients treated with liraglutide, another GLP-1 receptor agonist, have been reported in the postmarketing period; the data in these reports are insufficient to establish or exclude a causal relationship between MTC and GLP-1 receptor agonist use in humans. |
| Warfarin | drug interactions | Monitor drug levels of oral medications with a narrow therapeutic index (e.g., warfarin) when concomitantly administered with TRULICITY. |
Source: FDA drug label (Trulicity), Eli Lilly and Company, effective June 16, 2026 (SPL set 463050bd-2b1c-40f5-b3c3-0a04bb433309), via openFDA; the full label on DailyMed
What do FAERS reports show for dulaglutide?
The FDA Adverse Event Reporting System holds 88,160 reports that list dulaglutide among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 1,676 are coded as a death and 10,732 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as dulaglutide?
14 other medicines are given the same way (subcutaneous) and in the same FDA class as dulaglutide or labeled mainly for the same use (type 2 diabetes), the same class first. Type 2 diabetes lists all 52 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (subcutaneous) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Tirzepatide | Heart attack and coronary artery disease, Type 2 diabetes | none listed | $538.68 per mL 10 mg/0.5 mL pen | No current entry |
| Liraglutide | Heart attack and coronary artery disease, Type 2 diabetes | 9 labelers | $31.41 per mL 2-pak 18 mg/3 mL | In shortage |
| Semaglutide | Heart attack and coronary artery disease, Type 2 diabetes | none listed | $331.99 per mL 0.25-0.5 mg/dose (2 mg/3 mL) pen | A presentation being discontinued |
| Exenatide | Type 2 diabetes | 1 labeler | $300.17 per mL 10 mcg dose pen injection | No current entry |
| Insulin degludec and liraglutide | Type 2 diabetes | none listed | $85.89 per mL 100 unit-3.6 mg/mL pen | No current entry |
| Insulin glargine and lixisenatide | Type 2 diabetes | none listed | $57.06 per mL 100 unit-33 mcg/mL pen | No current entry |
| Insulin glargine | Type 2 diabetes | none listed | $2.90 per mL 100 pen | A presentation being discontinued |
| Insulin aspart | Type 2 diabetes | none listed | $6.95 per mL 100 unit/mL vial | No current entry |
Every medicine labeled for the same conditions as dulaglutide
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
How does dulaglutide compare with medicines for the same use?
3 side-by-side pages set dulaglutide beside a medicine whose label shares a use: approvals, generics, pharmacy cost, warnings and supply.
What next?
- Alternatives to dulaglutide
- 14 medicines for the same use
- Other GLP-1 receptor agonists
- the pharmacologic class, with prices and generics
- Dulaglutide side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other